Product Description
Mechanisms of Action: FR1 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Morphotek
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
Phase 2: Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer|Adenocarcinoma|Pituitary Diseases|Adenoma
Phase 1: Oncology Unspecified|Ovarian Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MORAB-003-J081-102 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-01-01 |
2020-06-22 |
Primary Endpoints|Treatments |
|
| MORAb-003-005 | P1 |
Completed |
Ovarian Cancer |
2012-08-01 |
2019-03-19 |
||
| JapicCTI-100986 | P1 |
Completed |
Oncology Unspecified |
2011-12-31 |
|||
| MORAb-003-001 | P1 |
Completed |
Ovarian Cancer |
2007-12-01 |
2019-03-21 |
Treatments |
|
| JapicCTI-142757 | P2 |
Unknown |
Ovarian Cancer |
2021-09-05 |
|||
| 2014-003812-36 | P2 |
Completed |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2020-08-13 |
2022-03-13 |
Treatments |
|
| MORAb-003-011 | P2 |
Completed |
Ovarian Cancer |
2019-05-31 |
50% |
2021-09-03 |
Patient Enrollment|Primary Endpoints |
| 2010-022229-13 | P2 |
Completed |
Adenocarcinoma |
2013-11-01 |
2025-06-25 |
||
| MORAb-003-007 | P2 |
Withdrawn |
Pituitary Diseases|Adenoma |
2013-06-01 |
2019-03-19 |
Treatments |
|
| 2008-005449-43 | P2 |
Terminated |
Ovarian Cancer |
2013-04-29 |
2022-03-12 |
Treatments |
|
| MORAb-003-002A | P2 |
Terminated |
Ovarian Cancer |
2013-03-05 |
2021-12-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| FLAIR | P2 |
Completed |
Adenocarcinoma |
2012-12-15 |
2020-08-21 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
|
| FAR-122 | P2 |
Terminated |
Ovarian Cancer |
2011-12-01 |
2019-03-18 |
||
| 2009-015825-36 | P2 |
Terminated |
Ovarian Cancer |
2011-10-27 |
2022-03-13 |
Treatments |
|
| 2006-003580-31 | P2 |
Completed |
Ovarian Cancer |
2010-02-02 |
2022-03-12 |
Treatments |
|
| MORAb-003-002 | P2 |
Completed |
Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer |
2010-02-01 |
2019-03-21 |
Treatments |
|
| 2008-005872-29 | P3 |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2015-02-24 |
2022-03-12 |
Treatments |
|
| JapicCTI-101358 | P3 |
Completed |
Ovarian Cancer |
2013-04-30 |
|||
| MORAb003-004 | P3 |
Terminated |
Ovarian Cancer |
2012-12-31 |
2022-12-31 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Trial Status |